---

Related Articles:

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

2013-11-01

[J. Neurol. Neurosurg. Psychiatr. 84(11) , 1186-91, (2013)]

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.

2012-01-01

[Drug Des. Devel. Ther. 6 , 175-86, (2012)]

Emerging injectable therapies for multiple sclerosis.

2013-11-01

[Lancet Neurol. 12(11) , 1115-26, (2013)]

Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

2013-03-01

[J. Pharm. Sci. 102(3) , 915-28, (2013)]

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

2013-01-01

[Drug Des. Devel. Ther. 7 , 131-8, (2013)]